Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Bladder Cancer

Free Subscription 14.06.2021 1 Acta Med Acad 1 Aging Dis 1 Am J Ind Med 1 Am Soc Clin Oncol Educ Book 1 Anal Biochem 1 Anticancer Res 2 Arch Esp Urol 1 BMC Bioinformatics 4 BMC Cancer 1 BMC Urol 1 Cancer Cell Int 1 Cancer Control 1 Cancer Manag Res 3 Cancer Med 1 Cancer Rep (Hoboken) 1 Cancer Treat Rev 6 Cancers (Basel) 1 Cells 1 Chin Med J (Engl) 1 Clin Adv Hematol Oncol 1 Clin Transplant 1 Cureus 6 Curr Urol 1 Diagnostics (Basel) 1 Drug Dev Res 1 Eur J Cancer Prev 2 Eur Urol 1 Eur Urol Focus 2 Eur Urol Oncol 2 Exp Ther Med 2 Front Mol Biosci 5 Front Oncol 1 Front Surg 1 Hinyokika Kiyo 1 Int J Clin Exp Pathol 1 Int J Environ Res Public Health 1 Int J Mol Sci 1 Investig Clin Urol 1 J Biochem Mol Toxicol 1 J Bone Jt Infect 1 J BUON 1 J Cancer Res Clin Oncol 1 J Clin Neurosci 1 J Endourol 1 J Exp Clin Cancer Res 1 J Magn Reson Imaging 1 J Manag Care Spec Pharm 1 J Nanosci Nanotechnol 1 J Natl Cancer Inst 1 J Pers Med 1 J Urol 1 J Vasc Surg Cases Innov Tech 1 JCO Clin Cancer Inform 1 Jpn J Clin Oncol 1 Lancet Oncol 1 Mol Biol Rep 1 Nat Commun 1 Oncoimmunology 1 Sci Rep 4 Urol Oncol 1 Urologia 1 Vaccines (Basel)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Med Acad

1. ULAMEC M, Murgic J, Novosel L, Tomic M, et al
   New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer.
   Acta Med Acad. 2021;50:143-156.
   PubMed         Abstract available
   
   

   
   Aging Dis

2. SHIH KW, Chen WC, Chang CH, Tai TE, et al
   Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.
   Aging Dis. 2021;12:868-885.
   PubMed         Abstract available
   
   

   
   Am J Ind Med

3. PARK RM, Carreon T, Hanley KW
   Risk assessment for o-toluidine and bladder cancer incidence.
   Am J Ind Med. 2021 Jun 10. doi: 10.1002/ajim.23265.
   PubMed         Abstract available
   
   

   
   Am Soc Clin Oncol Educ Book

4. HOFFMAN-CENSITS J, Kanesvaran R, Bangs R, Fashoyin-Aje L, et al
   Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer.
   Am Soc Clin Oncol Educ Book. 2021;41:e174-e181.
   PubMed         Abstract available
   
   

   
   Anal Biochem

5. ISLAM MK, Syed P, Dhondt B, Gidwani K, et al
   Detection of Bladder Cancer with Aberrantly Fucosylated ITGA3.
   Anal Biochem. 2021 Jun 5:114283. doi: 10.1016/j.ab.2021.114283.
   PubMed         Abstract available
   
   

   
   Anticancer Res

6. OKUBO K, Isono M, Asano T, REssING N, et al
   Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
   Anticancer Res. 2021;41:2901-2912.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

7. AIZCORBE GOMEZ M, Gutierrez Zurimendi G, Arruza Echevarria A
   [Clinicopathologic analysis of 5 cases of urachal adenocarcinoma.]
   Arch Esp Urol. 2021;74:535-540.
   PubMed         Abstract available
   
   
8. SANCHEZ VERDES P, Fernandez-Pello S, Gonzalez Rodriguez I, Salgado Plonski JJ, et al
   [Gross hematuria and usefulness of urinary cytology: Experience at hematuria one stop clinic.]
   Arch Esp Urol. 2021;74:470-476.
   PubMed         Abstract available
   
   

   
   BMC Bioinformatics

9. LIN JY, Juo BR, Yeh YH, Fu SH, et al
   Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics.
   BMC Bioinformatics. 2021;22:305.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    PubMed         Abstract available
    
    
11. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    PubMed         Abstract available
    
    
12. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    PubMed         Abstract available
    
    
13. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    PubMed         Abstract available
    
    

    
    BMC Urol

14. WU H, Jiang W, Ji G, Xu R, et al
    Exploring microRNA target genes and identifying hub genes in bladder cancer based on bioinformatic analysis.
    BMC Urol. 2021;21:90.
    PubMed         Abstract available
    
    

    
    Cancer Cell Int

15. DU Y, Jiang X, Wang B, Cao J, et al
    The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer.
    Cancer Cell Int. 2021;21:283.
    PubMed         Abstract available
    
    

    
    Cancer Control

16. HUANG J, Zhao L, Wang K, Sun J, et al
    Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer.
    Cancer Control. 2021;28:10732748211021078.
    PubMed         Abstract available
    
    

    
    Cancer Manag Res

17. HAN X, Liu J, Liu Y, Mou L, et al
    LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p.
    Cancer Manag Res. 2021;13:4393-4401.
    PubMed         Abstract available
    
    

    
    Cancer Med

18. HEKTOEN HH, Robsahm TE, Stenehjem JS, Axcrona K, et al
    Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
    Cancer Med. 2021 Jun 3. doi: 10.1002/cam4.3960.
    PubMed         Abstract available
    
    
19. ZUO Y, Xu X, Chen M, Qi L, et al
    The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo.
    Cancer Med. 2021 Jun 8. doi: 10.1002/cam4.3955.
    PubMed         Abstract available
    
    
20. VELMAHOS CS, Badgeley M, Lo YC
    Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.
    Cancer Med. 2021 Jun 10. doi: 10.1002/cam4.4044.
    PubMed         Abstract available
    
    

    
    Cancer Rep (Hoboken)

21. PHAM QT, Taniyama D, Akabane S, Harada K, et al
    TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.
    Cancer Rep (Hoboken). 2021 Jun 7:e1417. doi: 10.1002/cnr2.1417.
    PubMed         Abstract available
    
    

    
    Cancer Treat Rev

22. GRIVAS P, Agarwal N, Pal S, Kalebasty AR, et al
    Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Cancer Treat Rev. 2021;97:102187.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

23. MIYAKE M, Nishimura N, Iida K, Fujii T, et al
    Intravesical Bacillus Calmette-Guerin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
24. LORAS A, Segovia C, Ruiz-Cerda JL
    Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
25. ZHAO Z, Wang Y, Zhang JJ, Huang XY, et al
    Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
26. PONES M, D'Andrea D, Mori K, Abufraj M, et al
    Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
27. BARANI M, Hosseinikhah SM, Rahdar A, Farhoudi L, et al
    Nanotechnology in Bladder Cancer: Diagnosis and Treatment.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
28. CANNON-ALBRIGHT LA, Teerlink CC, Stevens J, Huang FW, et al
    A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    

    
    Cells

29. IDE H, Miyamoto H
    Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.
    Cells. 2021;10.
    PubMed         Abstract available
    
    

    
    Chin Med J (Engl)

30. ZHENG XN, Qiu S, Tang LS, Ai JZ, et al
    Tumor microenvironment-based drug discovery: a novel insight into bladder cancer immunotherapy.
    Chin Med J (Engl). 2021 Jun 2. pii: 00029330-900000000-98594.
    PubMed        
    
    

    
    Clin Adv Hematol Oncol

31. ROSENBERG JE
    New treatments for patients with progressive metastatic urothelial carcinoma.
    Clin Adv Hematol Oncol. 2021;19:180-183.
    PubMed        
    
    

    
    Clin Transplant

32. ALKASSIS M, Abi Tayeh G, Khalil N, Mansour R, et al
    The Safety and Efficacy of Bacillus Calmette-Guerin Intravesical Therapy in Kidney Transplant Recipients with Superficial Bladder Cancer.
    Clin Transplant. 2021 May 29:e14377. doi: 10.1111/ctr.14377.
    PubMed         Abstract available
    
    

    
    Cureus

33. GUPTA S, Singh B, Bhatt H, Singh S, et al
    A Case of Systemic Toxicity Related to Intravesical Bacillus Calmette-Guerin for the Treatment of Bladder Cancer.
    Cureus. 2021;13:e15321.
    PubMed         Abstract available
    
    

    
    Curr Urol

34. MOHAMED DO, Sayed MM, Abdelkawi IF, Elshoieby MH, et al
    Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer.
    Curr Urol. 2021;15:11-15.
    PubMed         Abstract available
    
    
35. SHANTHARAM G, Amin A, Pereira J, Kott O, et al
    Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure.
    Curr Urol. 2021;15:33-38.
    PubMed         Abstract available
    
    
36. SCIARRA A, Di Lascio G, Del Giudice F, Leoncini PP, et al
    Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review.
    Curr Urol. 2021;15:22-32.
    PubMed         Abstract available
    
    
37. MATSUOKA Y, Taoka R, Kohashiguchi K, Tohi Y, et al
    Efficacy and toxicity of intravesical Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer.
    Curr Urol. 2021;15:16-21.
    PubMed         Abstract available
    
    
38. QI Y, Tang D
    Commentary: Bladder cancer.
    Curr Urol. 2021;15:1.
    PubMed        
    
    
39. EL KHATIB S
    In vivo photobleaching kinetics and epithelial biodistribution of hexylaminolevulinate-induced protoporphyrin IX in rat bladder cancer.
    Curr Urol. 2021;15:2-10.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

40. CUCCURULLO V, Di Stasio GD, Manti F, Arcuri P, et al
    The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.
    Diagnostics (Basel). 2021;11.
    PubMed         Abstract available
    
    

    
    Drug Dev Res

41. YE W, Chen L, Feng C, Liang T, et al
    CircMYLK promotes the growth, migration, invasion, and survival of bladder cancer cells by upregulating CCND3 level via competitively binding to miR-34a.
    Drug Dev Res. 2021 May 30. doi: 10.1002/ddr.21835.
    PubMed         Abstract available
    
    

    
    Eur J Cancer Prev

42. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic.
    Eur J Cancer Prev. 2021 Jun 1. pii: 00008469-900000000-99039.
    PubMed         Abstract available
    
    

    
    Eur Urol

43. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
    Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
    PubMed        
    
    
44. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
    Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

45. KOZIKOWSKI M, Suarez-Ibarrola R, Osiecki R, Bilski K, et al
    Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2021 Jun 4. pii: S2405-4569(21)00157.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

46. CONTIERI R, Paciotti M, Lughezzani G, Buffi NM, et al
    Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience.
    Eur Urol Oncol. 2021 May 28. pii: S2588-9311(21)00108.
    PubMed         Abstract available
    
    
47. JOBCZYK M, Stawiski K, Kaszkowiak M, Rajwa P, et al
    Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Jun 3. pii: S2588-9311(21)00112.
    PubMed         Abstract available
    
    

    
    Exp Ther Med

48. BRATU O, Marcu D, Anghel R, Spinu D, et al
    Tumoral markers in bladder cancer (Review).
    Exp Ther Med. 2021;22:773.
    PubMed         Abstract available
    
    
49. CHAO Y, Ou Q, Shang J
    Expression and prognostic value of SULT1A2 in bladder cancer.
    Exp Ther Med. 2021;22:779.
    PubMed         Abstract available
    
    

    
    Front Mol Biosci

50. SEGATTO NV, Bender CB, Seixas FK, Schachtschneider K, et al
    Perspective: Humanized Pig Models of Bladder Cancer.
    Front Mol Biosci. 2021;8:681044.
    PubMed         Abstract available
    
    
51. LIU J, Ma H, Meng L, Liu X, et al
    Construction and External Validation of a Ferroptosis-Related Gene Signature of Predictive Value for the Overall Survival in Bladder Cancer.
    Front Mol Biosci. 2021;8:675651.
    PubMed         Abstract available
    
    

    
    Front Oncol

52. JIANG LR, Zhang N, Chen ST, He J, et al
    PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions.
    Front Oncol. 2021;11:679928.
    PubMed         Abstract available
    
    
53. ZHENG Z, Xu F, Gu Z, Yan Y, et al
    Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer.
    Front Oncol. 2021;11:619893.
    PubMed         Abstract available
    
    
54. EPAILLARD N, Parent P, Loriot Y, Lavaud P, et al
    Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
    Front Oncol. 2021;11:671969.
    PubMed         Abstract available
    
    
55. GUO C, Li X, Xie J, Liu D, et al
    Long Noncoding RNA SNHG1 Activates Autophagy and Promotes Cell Invasion in Bladder Cancer.
    Front Oncol. 2021;11:660551.
    PubMed         Abstract available
    
    
56. LI Y, Sun L, Guo X, Mo N, et al
    Frontiers in Bladder Cancer Genomic Research.
    Front Oncol. 2021;11:670729.
    PubMed         Abstract available
    
    

    
    Front Surg

57. CHAI CA, Yeoh WS, Rajandram R, Aung KP, et al
    Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study.
    Front Surg. 2021;8:659292.
    PubMed         Abstract available
    
    

    
    Hinyokika Kiyo

58. SASAKI Y, Kadoriku F, Fukatani Y, Yamamoto H, et al
    [A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration].
    Hinyokika Kiyo. 2021;67:163-166.
    PubMed         Abstract available
    
    

    
    Int J Clin Exp Pathol

59. LIU Z, Liu X, Cai R, Liu M, et al
    Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis.
    Int J Clin Exp Pathol. 2021;14:551-566.
    PubMed         Abstract available
    
    

    
    Int J Environ Res Public Health

60. NIK AB KADIR MN, Mohd Hairon S, Yaacob NM, Ab Manan A, et al
    Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.
    Int J Environ Res Public Health. 2021;18.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

61. SCHNEIDER L, Liu J, Zhang C, Azoitei A, et al
    The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion.
    Int J Mol Sci. 2021;22.
    PubMed         Abstract available
    
    

    
    Investig Clin Urol

62. KIM HS, Seo HK
    Emerging treatments for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer.
    Investig Clin Urol. 2021 May 27. pii: 62.e49. doi: 10.4111/icu.20200602.
    PubMed         Abstract available
    
    

    
    J Biochem Mol Toxicol

63. ZHAO X, Li G, Chong T, Xue L, et al
    TMEM88 exhibits an antiproliferative and anti-invasive effect in bladder cancer by downregulating Wnt/beta-catenin signaling.
    J Biochem Mol Toxicol. 2021 May 31:e22835. doi: 10.1002/jbt.22835.
    PubMed         Abstract available
    
    

    
    J Bone Jt Infect

64. STERN R, Roscoe C, Misch EA
    Mycobacterium bovis BCG osteoarticular infection complicating immune therapy for bladder cancer: a case report.
    J Bone Jt Infect. 2021;6:107-110.
    PubMed         Abstract available
    
    

    
    J BUON

65. XU A, Yang GG, Zhang Y, Zhao ST, et al
    Heptaphylline suppresses the proliferation and migration of human bladder cancer cells via induction of intrinsic apoptosis, autophagy and inhibition of beta-catenin signalling pathway.
    J BUON. 2021;26:646.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

66. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
    High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
    J Cancer Res Clin Oncol. 2021 Jun 2. pii: 10.1007/s00432-021-03661.
    PubMed         Abstract available
    
    

    
    J Clin Neurosci

67. LIM JX, Chan SKS, Hwang PYK
    Trans-sulcal parafascicular approach to subcortical lesions.
    J Clin Neurosci. 2021;86:45-49.
    PubMed         Abstract available
    
    

    
    J Endourol

68. MORELLI M, Baboudjian M, Vanacore D, Gondran-Tellier B, et al
    Early PDD Cystoscopy after BCG Induction for High-risk Non-Muscle Invasive Bladder Cancer Significantly Increased the Detection of BCG-refractory Tumors.
    J Endourol. 2021 Jun 9. doi: 10.1089/end.2021.0313.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

69. PEIXOTO A, Ferreira D, Azevedo R, Freitas R, et al
    Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.
    J Exp Clin Cancer Res. 2021;40:191.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

70. CAI Q, Wen Z, Huang Y, Li M, et al
    Investigation of Synthetic Magnetic Resonance Imaging Applied in the Evaluation of the Tumor Grade of Bladder Cancer.
    J Magn Reson Imaging. 2021 Jun 3. doi: 10.1002/jmri.27770.
    PubMed         Abstract available
    
    

    
    J Manag Care Spec Pharm

71. BEINFELD M, Atlas SJ, Touchette D, McKenna A, et al
    The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.
    J Manag Care Spec Pharm. 2021;27:797-804.
    PubMed         Abstract available
    
    

    
    J Nanosci Nanotechnol

72. WANG L, Tao H, Li Z, Lei Y, et al
    Preparation of Composite Cypate Nanoparticles and Its Application in the Treatment of Pediatric Bladder Tumors.
    J Nanosci Nanotechnol. 2021;21:868-877.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

73. APPLEMAN LJ
    Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena.
    J Natl Cancer Inst. 2021;113:7-8.
    PubMed        
    
    

    
    J Pers Med

74. JUTTE H, Reike M, Wirtz RM, Kriegmair M, et al
    KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Pers Med. 2021;11.
    PubMed         Abstract available
    
    

    
    J Urol

75. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    PubMed         Abstract available
    
    

    
    J Vasc Surg Cases Innov Tech

76. PHAM STD, Lee A, Struminger JS, Belkoff KM, et al
    Mycotic infrarenal aortic aneurysm due to mycobacterium after intravesical treatment for bladder cancer.
    J Vasc Surg Cases Innov Tech. 2021;7:354-356.
    PubMed         Abstract available
    
    

    
    JCO Clin Cancer Inform

77. NOONE AM, Lam CJK, Smith AB, Nielsen ME, et al
    Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries.
    JCO Clin Cancer Inform. 2021;5:641-653.
    PubMed         Abstract available
    
    

    
    Jpn J Clin Oncol

78. ANNO T, Kikuchi E, Shigeta K, Ogihara K, et al
    Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery.
    Jpn J Clin Oncol. 2021;51:984-991.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

79. BALAR AV, Kamat AM, Kulkarni GS, Uchio EM, et al
    Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Lancet Oncol. 2021 May 26. pii: S1470-2045(21)00147.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

80. EL-SHAL AS, Shalaby SM, Abouhashem SE, Elbary EHA, et al
    Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer.
    Mol Biol Rep. 2021 Jun 4. pii: 10.1007/s11033-021-06451.
    PubMed         Abstract available
    
    

    
    Nat Commun

81. BRISUDA A, Ho JCS, Kandiyal PS, Ng JT, et al
    Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex.
    Nat Commun. 2021;12:3427.
    PubMed         Abstract available
    
    

    
    Oncoimmunology

82. ZHOU L, Xu B, Liu Y, Wang Z, et al
    Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
    Oncoimmunology. 2021;10:1915574.
    PubMed         Abstract available
    
    

    
    Sci Rep

83. LAI WH, Fang CY, Chou MC, Lin MC, et al
    Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy.
    Sci Rep. 2021;11:11889.
    PubMed         Abstract available
    
    

    
    Urol Oncol

84. MOUSSA M, Chakra MA, Saad W, Dellis A, et al
    The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Urol Oncol. 2021 May 29. pii: S1078-1439(21)00183.
    PubMed         Abstract available
    
    
85. MATULEWICZ RS, Ravvaz K, Weissert JA, Porten S, et al
    Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy.
    Urol Oncol. 2021 May 27. pii: S1078-1439(21)00185.
    PubMed         Abstract available
    
    
86. STEINBERG RL, Packiam VT, Thomas LJ, Brooks N, et al
    Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
    Urol Oncol. 2021 Jun 3. pii: S1078-1439(21)00134.
    PubMed         Abstract available
    
    
87. CLAPS F, Rai S, Mir MC, van Rhijn BWG, et al
    Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy.
    Urol Oncol. 2021 May 25. pii: S1078-1439(21)00184.
    PubMed         Abstract available
    
    

    
    Urologia

88. SERRETTA V, Berardinis E, Simonato A, Guarneri A, et al
    A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis.
    Urologia. 2021 Jun 2:3915603211022285. doi: 10.1177/03915603211022285.
    PubMed         Abstract available
    
    

    
    Vaccines (Basel)

89. KLINGER D, Hill BL, Barda N, Halperin E, et al
    Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.
    Vaccines (Basel). 2021;9.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: